Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats estrogen receptor-positive metastatic breast cancer. Sold as Nolvadex, Soltamox. Every FDA application for this active ingredient: 2 branded and 12 generic.
As of Nov 15, 2026, FDA lists 14 applications for Tamoxifen Citrate (sold as Nolvadex, Soltamox), first approved Dec 30, 1977, with 11 new uses approved and 0 published complete response letters.
First approved: Dec 30, 1977
Applications: 14
New uses approved: 11
Complete response letters: 0
Medicare spending, 2025: $10.8M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Tamoxifen Citrate
Part D
$10.1M
-1%
101,814
Soltamox
Part D
$628K
+19%
102
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
TAMOXIFEN 10 MG TABLET: $0.132 per unitGeneric · -13% in a year
TAMOXIFEN 20 MG TABLET: $0.275 per unitGeneric · -5% in a year
Clinical Trials
133 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Astrazeneca
Mylan
Roxane
Teva
Apotex
Zydus Pharms
Eugia Pharma